Johnson & Johnson Long Term Debt 2010-2022 | JNJ
Johnson & Johnson long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
- Johnson & Johnson long term debt for the quarter ending December 31, 2022 was $26.888B, a 10.33% decline year-over-year.
- Johnson & Johnson long term debt for 2022 was $26.888B, a 10.33% decline from 2021.
- Johnson & Johnson long term debt for 2021 was $29.985B, a 8.12% decline from 2020.
- Johnson & Johnson long term debt for 2020 was $32.635B, a 23.18% increase from 2019.
Johnson & Johnson Annual Long Term Debt
(Millions of US $) |
| 2022 |
$26,888 |
| 2021 |
$29,985 |
| 2020 |
$32,635 |
| 2019 |
$26,494 |
| 2018 |
$27,684 |
| 2017 |
$30,675 |
| 2016 |
$22,442 |
| 2015 |
$12,857 |
| 2014 |
$15,122 |
| 2013 |
$13,328 |
| 2012 |
$11,489 |
| 2011 |
$12,969 |
| 2010 |
$9,156 |
| 2009 |
$8,223 |
Johnson & Johnson Quarterly Long Term Debt
(Millions of US $) |
| 2022-12-31 |
$26,888 |
| 2022-09-30 |
$27,603 |
| 2022-06-30 |
$28,292 |
| 2022-03-31 |
$28,851 |
| 2021-12-31 |
$29,985 |
| 2021-09-30 |
$30,130 |
| 2021-06-30 |
$30,310 |
| 2021-03-31 |
$30,263 |
| 2020-12-31 |
$32,635 |
| 2020-09-30 |
$32,680 |
| 2020-06-30 |
$25,062 |
| 2020-03-31 |
$25,393 |
| 2019-12-31 |
$26,494 |
| 2019-09-30 |
$26,919 |
| 2019-06-30 |
$27,699 |
| 2019-03-31 |
$27,660 |
| 2018-12-31 |
$27,684 |
| 2018-09-30 |
$29,480 |
| 2018-06-30 |
$29,405 |
| 2018-03-31 |
$29,837 |
| 2017-12-31 |
$30,675 |
| 2017-09-30 |
$26,675 |
| 2017-06-30 |
$27,363 |
| 2017-03-31 |
$27,015 |
| 2016-12-31 |
$22,442 |
| 2016-09-30 |
$23,546 |
| 2016-06-30 |
$24,535 |
| 2016-03-31 |
$20,233 |
| 2015-12-31 |
$12,857 |
| 2015-09-30 |
$14,073 |
| 2015-06-30 |
$14,085 |
| 2015-03-31 |
$14,938 |
| 2014-12-31 |
$15,122 |
| 2014-09-30 |
$13,152 |
| 2014-06-30 |
$13,303 |
| 2014-03-31 |
$13,343 |
| 2013-12-31 |
$13,328 |
| 2013-09-30 |
$9,748 |
| 2013-06-30 |
$9,643 |
| 2013-03-31 |
$11,363 |
| 2012-12-31 |
$11,489 |
| 2012-09-30 |
$11,428 |
| 2012-06-30 |
$11,525 |
| 2012-03-31 |
$13,010 |
| 2011-12-31 |
$12,969 |
| 2011-09-30 |
$13,031 |
| 2011-06-30 |
$13,680 |
| 2011-03-31 |
$9,255 |
| 2010-12-31 |
$9,156 |
| 2010-09-30 |
$9,182 |
| 2010-06-30 |
$7,937 |
| 2010-03-31 |
$8,059 |
| 2009-12-31 |
$8,223 |
| 2009-09-30 |
$8,259 |
| 2009-06-30 |
$8,179 |
| 2009-03-31 |
$8,052 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.576B |
$94.943B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
